Kolexia
Berdah Jean Oncologie médicale
Berdah Jean
Oncologie médicale
Centre Hospitalier De Castelluccio
Ajaccio, France
79 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la prostate Adénocarcinome Carcinomes Tumeurs prostatiques résistantes à la castration Néphrocarcinome Métastase tumorale Tumeurs du rectum Récidive tumorale locale Invasion tumorale

Collaborateurs

Voir plus
Fizazi Karim
Fizazi Karim
Gustave-Roussy, Villejuif, France
Gravis-Mescam Gwenaelle
Gravis-Mescam Gwenaelle
Centre Paoli-Calmettes, Marseille, France
Duberge Thomas
Duberge Thomas
Cds Medical, Toulon, France
Combes Francois
Combes Francois
Centre D'urologie Urovar, Toulon, France

Industries

Voir plus
Janssen
40 collaboration(s)
Dernière en 2023
Bayer
15 collaboration(s)
Dernière en 2023
BMS
12 collaboration(s)
Dernière en 2021
Astellas
9 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
PEACE1: A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
Essai Clinique (Ipsen)   07 novembre 2023
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
European urology   02 juin 2023
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.
Clinical genitourinary cancer   07 mai 2023
PEACE-4: A Phase III Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
Essai Clinique (Gustave-Roussy)   10 février 2023
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse: Phase III Randomized Study Of Adjuvant Hormonal Therapy With And Without Docetaxel And Estramustine In Patients With Advanced Prostate Cancer Or With A High Risk Of Relapse
Essai Clinique (Sanofi)   17 janvier 2023
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
European journal of cancer (Oxford, England : 1990)   13 janvier 2023
L’intensification du traitement du cancer de la prostate métastatique hormonosensible (MHSPC) est devenue un standard de prise en charge en France (étude profile)
116e congrès français d'urologie   01 novembre 2022
PEACE2: A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
Essai Clinique (Sanofi)   28 octobre 2022
1421P Effect of abiraterone-prednisone in metastatic castration-sensitive prostate cancer (mCSPC) with neuroendocrine and very high-risk features in the PEACE-1 trial
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022